S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.00 (+0.16%)
AAPL   173.97 (-0.33%)
MSFT   289.78 (-0.53%)
META   174.50 (-0.20%)
GOOGL   120.04 (+0.41%)
AMZN   142.23 (+0.09%)
TSLA   908.07 (-0.43%)
NVDA   187.54 (+2.29%)
NIO   19.92 (-0.80%)
BABA   90.61 (+0.94%)
AMD   100.36 (+2.13%)
MU   62.93 (+2.13%)
T   18.41 (-0.05%)
CGC   3.81 (-6.16%)
F   16.13 (+0.62%)
GE   79.42 (-0.63%)
DIS   122.51 (-0.24%)
AMC   19.33 (-9.50%)
PYPL   99.73 (+0.31%)
PFE   48.54 (-1.48%)
NFLX   245.00 (+1.60%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.00 (+0.16%)
AAPL   173.97 (-0.33%)
MSFT   289.78 (-0.53%)
META   174.50 (-0.20%)
GOOGL   120.04 (+0.41%)
AMZN   142.23 (+0.09%)
TSLA   908.07 (-0.43%)
NVDA   187.54 (+2.29%)
NIO   19.92 (-0.80%)
BABA   90.61 (+0.94%)
AMD   100.36 (+2.13%)
MU   62.93 (+2.13%)
T   18.41 (-0.05%)
CGC   3.81 (-6.16%)
F   16.13 (+0.62%)
GE   79.42 (-0.63%)
DIS   122.51 (-0.24%)
AMC   19.33 (-9.50%)
PYPL   99.73 (+0.31%)
PFE   48.54 (-1.48%)
NFLX   245.00 (+1.60%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.00 (+0.16%)
AAPL   173.97 (-0.33%)
MSFT   289.78 (-0.53%)
META   174.50 (-0.20%)
GOOGL   120.04 (+0.41%)
AMZN   142.23 (+0.09%)
TSLA   908.07 (-0.43%)
NVDA   187.54 (+2.29%)
NIO   19.92 (-0.80%)
BABA   90.61 (+0.94%)
AMD   100.36 (+2.13%)
MU   62.93 (+2.13%)
T   18.41 (-0.05%)
CGC   3.81 (-6.16%)
F   16.13 (+0.62%)
GE   79.42 (-0.63%)
DIS   122.51 (-0.24%)
AMC   19.33 (-9.50%)
PYPL   99.73 (+0.31%)
PFE   48.54 (-1.48%)
NFLX   245.00 (+1.60%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.00 (+0.16%)
AAPL   173.97 (-0.33%)
MSFT   289.78 (-0.53%)
META   174.50 (-0.20%)
GOOGL   120.04 (+0.41%)
AMZN   142.23 (+0.09%)
TSLA   908.07 (-0.43%)
NVDA   187.54 (+2.29%)
NIO   19.92 (-0.80%)
BABA   90.61 (+0.94%)
AMD   100.36 (+2.13%)
MU   62.93 (+2.13%)
T   18.41 (-0.05%)
CGC   3.81 (-6.16%)
F   16.13 (+0.62%)
GE   79.42 (-0.63%)
DIS   122.51 (-0.24%)
AMC   19.33 (-9.50%)
PYPL   99.73 (+0.31%)
PFE   48.54 (-1.48%)
NFLX   245.00 (+1.60%)
NASDAQ:GH

Guardant Health - GH Stock Forecast, Price & News

$50.38
-1.04 (-2.02%)
(As of 08/18/2022 03:59 PM ET)
Add
Compare
Today's Range
$48.74
$50.52
50-Day Range
$35.88
$55.04
52-Week Range
$27.65
$133.82
Volume
26,480 shs
Average Volume
1.04 million shs
Market Capitalization
$5.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.00

Guardant Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
138.0% Upside
$119.00 Price Target
Short Interest
Healthy
4.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.40mentions of Guardant Health in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$240,210 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.95) to ($5.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

311th out of 1,119 stocks

Medical Laboratories Industry

10th out of 28 stocks

GH stock logo

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Guardant Health Price Performance

NASDAQ:GH traded down $1.75 during mid-day trading on Wednesday, hitting $51.42. 835,610 shares of the stock traded hands, compared to its average volume of 1,262,891. The company has a quick ratio of 5.83, a current ratio of 6.18 and a debt-to-equity ratio of 3.56. Guardant Health has a 12-month low of $27.65 and a 12-month high of $133.82. The company has a market cap of $5.26 billion, a PE ratio of -9.56 and a beta of 0.81. The business's 50-day moving average price is $46.33 and its 200 day moving average price is $54.00.

Guardant Health (NASDAQ:GH - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($2.25) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by ($1.00). Guardant Health had a negative return on equity of 99.90% and a negative net margin of 135.03%. The company had revenue of $109.14 million during the quarter, compared to analysts' expectations of $105.14 million. During the same period in the prior year, the firm earned ($0.96) EPS. Guardant Health's quarterly revenue was up 18.5% on a year-over-year basis. On average, analysts expect that Guardant Health will post -5.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GH shares. OTR Global downgraded shares of Guardant Health to a "positive" rating in a research note on Monday, August 1st. The Goldman Sachs Group reduced their target price on shares of Guardant Health from $90.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, August 8th. Piper Sandler started coverage on shares of Guardant Health in a research note on Thursday, June 2nd. They issued an "overweight" rating and a $65.00 target price for the company. Citigroup reduced their target price on shares of Guardant Health from $120.00 to $100.00 in a research note on Friday, May 6th. Finally, Morgan Stanley reduced their target price on shares of Guardant Health from $85.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, August 8th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and a consensus target price of $119.00.

Insiders Place Their Bets

In other Guardant Health news, SVP Amelia Merrill sold 4,500 shares of the business's stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $53.38, for a total value of $240,210.00. Following the completion of the transaction, the senior vice president now owns 24,708 shares of the company's stock, valued at approximately $1,318,913.04. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.90% of the company's stock.

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock News Headlines

SVP Of Guardant Health Makes $484K Sale
Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
Why Guardant Health Stock Was So Healthy Today
Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
Why Shares of Guardant Health Dropped 33.6% in May
What 6 Analyst Ratings Have To Say About Guardant Health
Why Guardant Health Stock Is Crashing Today
Guardant Health Q1 2022 Earnings Preview
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings
8/04/2022
Today
8/18/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
1,373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$119.00
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+136.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-405,670,000.00
Net Margins
-135.03%
Pretax Margin
-130.34%

Debt

Sales & Book Value

Annual Sales
$373.65 million
Book Value
$3.12 per share

Miscellaneous

Free Float
96,189,000
Market Cap
$5.15 billion
Optionable
Not Optionable
Beta
0.81

Key Executives

  • Dr. Helmy Eltoukhy Ph.D. (Age 43)
    Co-Founder, Co-CEO & Chairman
    Comp: $13.66k
  • Dr. AmirAli Talasaz Ph.D. (Age 42)
    Co-CEO & Director
    Comp: $13.27k
  • Mr. Michael Bell (Age 53)
    Chief Financial Officer
    Comp: $1.2M
  • Mr. John G. Saia (Age 49)
    Chief Legal Officer
    Comp: $641.22k
  • Dr. Craig Eagle M.D. (Age 55)
    Chief Medical Officer
    Comp: $2.88M
  • Mr. Christopher Freeman (Age 48)
    Chief Commercial Officer of Oncology Bus.
    Comp: $740.23k
  • Mr. Andy Ament
    Sr. VP of Operations
  • Darya Chudova
    Sr. VP of Technology
  • Mr. Kumud Kalia
    Chief Information Officer
  • Ms. Jennifer Higgins
    VP of Public Affairs













GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price forecast for 2022?

12 brokers have issued 12-month target prices for Guardant Health's shares. Their GH share price forecasts range from $65.00 to $165.00. On average, they expect the company's share price to reach $119.00 in the next year. This suggests a possible upside of 131.4% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2022?

Guardant Health's stock was trading at $100.02 at the start of the year. Since then, GH shares have decreased by 48.6% and is now trading at $51.42.
View the best growth stocks for 2022 here
.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GH earnings forecast
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, August, 4th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by $1.00. The firm had revenue of $109.14 million for the quarter, compared to the consensus estimate of $105.14 million. Guardant Health had a negative trailing twelve-month return on equity of 99.90% and a negative net margin of 135.03%. The business's revenue for the quarter was up 18.5% compared to the same quarter last year. During the same period last year, the business earned ($0.96) earnings per share.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2022 earnings guidance on Thursday, August, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.29 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (3.17%), Price T Rowe Associates Inc. MD (1.54%), Pictet Asset Management SA (1.01%), Massachusetts Financial Services Co. MA (0.98%), Northern Trust Corp (0.41%) and Integral Health Asset Management LLC (0.38%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $51.42.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $5.26 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis.

How many employees does Guardant Health have?

The company employs 1,373 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.